0001069183false00010691832024-05-062024-05-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

May 6, 2024

Date of Report (Date of earliest event reported)

Axon Enterprise, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-16391

86-0741227

(State or other jurisdiction of
incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

17800 N. 85th St.

Scottsdale, Arizona 85255

(Address of principal executive offices, including zip code)

(480) 991-0797

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.00001 Par Value

AXON

The Nasdaq Global Select Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Item 2.02 Results of Operations and Financial Condition

On May 6, 2024, Axon Enterprise, Inc. (the “Company” or “Axon”) issued a shareholder letter regarding the Company’s financial results for its first quarter ended March 31, 2024. The full text of the letter, together with the audited consolidated statements of operations, segment reporting, balance sheets, cash flow information, statistical measures and reconciliations of GAAP to non-GAAP financial measures are attached hereto as Exhibit 99.1.

The information pursuant to Item 2.02 in this report on Form 8-K is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

Item 9.01 Financial Statements and Exhibits

(d)           Exhibits

Exhibit
Number

    

Exhibit Description

99.1

Shareholder letter dated May 6, 2024

104

The cover page from this Current Report on Form 8-K, formatted as Inline XBRL

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 6, 2024

Axon Enterprise, Inc.

  

By:

/s/ BRITTANY BAGLEY

Brittany Bagley

Chief Operating Officer and Chief Financial Officer

Exhibit 99.1

CONTACT:

Investor Relations

Axon Enterprise, Inc.

IR@axon.com

Axon reports Q1 2024 revenue of $461 million, up 34% year over year, raises outlook

Axon Cloud & Services revenue grows 52% to $176 million
Annual recurring revenue grows 50% to $825 million
Net income of $133 million supports non-GAAP net income of $89 million and Adjusted EBITDA of $109 million
Raises full year revenue outlook to a range of $1.94 billion to $1.99 billion, up from $1.88 billion to $1.94 billion

Fellow shareholders,

Axon is pleased to report a strong start to 2024 with another quarter of impressive financial performance supporting an improved outlook for FY 2024, and continued long-term innovation that we expect will fuel our growth for years to come. First quarter revenue growth of 34% marks our 9th consecutive quarter of growth above 25%, and we delivered improved profitability with first quarter net income margin of 28.9% and Adjusted EBITDA margin of 23.6%.

Axon Cloud & Services revenue of $176 million grew 52% year over year, more than doubling over the last two years. Our software revenue growth is driven by both adoption of new products from our existing customers and attracting new users to our ecosystem. Our net revenue retention remains a powerful driver at 122%, and we aim to sustain robust software growth over the longer term through disruptive product innovation. This includes recently announced significant new advancements leveraging artificial intelligence (“AI”) and virtual reality (“VR”) to enhance officer training and productivity, and our planned acquisition of Dedrone, which will help make our vision for Drone as a First Responder (“DFR”) a reality.

Our integrated subscription plans drive value for our customers beyond what can be achieved through disparate point solutions and our software growth is also linked to record demand for our TASER and Sensors products. TASER revenue of $179 million grew 33% year over year propelled by demand for TASER 10. Sensors & Other revenue of $106 million grew 14% year over year driven by adoption of Axon Body 4.

Axon’s consistent growth at increasing scale is a result of execution on our strategy to build the modern technology ecosystem for public safety and trusting partnership with our customers. Their feedback energizes our teams to work on the next innovations to help drive better outcomes, and we see tailwinds across our product portfolio now and in the future. Looking ahead, we aim to deliver improved financial performance and are increasing our revenue and Adjusted EBITDA expectations for the year. We are humbled to provide this update and share more detail, below.

Select Highlights

Axon Week 2024

In April, we hosted our ninth annual user conference, combining our long-running Axon Accelerate and second annual TASERCON into one main event — Axon Week. Our largest user conference to date welcomed over 1,400 customer attendees and featured 99 breakout sessions to demonstrate the Axon ecosystem and facilitate broader conversations about public safety. Our expanding user base was also on display, with strong attendance across emerging customer verticals for Axon. Over 20% of our customer attendees came from verticals outside of U.S. state and local law enforcement, including international, U.S. federal, justice, corrections and enterprise.

Axon Week has become one of the largest user conferences in public safety and is an exciting way to bring our customers together with our teams to share ideas, and showcase the full power of the Axon ecosystem. Each year, we also use this event to introduce and highlight new products and solution applications to our customers. Our


announcements from Axon Week 2024 include advancements to our VR training portfolio, an improved mobile app, and Draft One, which we explore in greater detail next in this letter.

“Our philosophy across all of these things is simple: Saving Seconds Saves Lives.” - Rick Smith, Axon Founder and CEO

Product Innovation Highlights

Draft One

Axon’s latest AI-driven product, Draft One, is a revolutionary new software tool that drafts high-quality police report narratives in seconds based on auto-transcribed body-worn camera audio. Draft One leverages the advanced power of Generative AI and includes a range of critical safeguards, requiring every report to be reviewed and approved by a human officer, ensuring accuracy and accountability of the information before reports are submitted.

We believe Draft One is a valuable tool that will drive immediate productivity gains for our customers. Reporting is a critical component of good police work; however, it has become a significant part of the job that officers commonly refer to as "burdensome." Axon found that every week officers in the United States can spend about 40% of their time — or 15 hours per week — on what is essentially data entry. Additionally, prosecutors and defense attorneys have shared that they welcome the quality improvement of Draft One reports as they can help support and accelerate the judicial process.

“Draft One is the next evolution in report-writing; as significant as when law enforcement moved from the typewriter to the word processor.”

— Captain Brian Gossard, Lafayette Indiana Police

“You come on this job wanting to make an impact. You don’t come on this job wanting to write reports. So, this AI feature, I’m super excited about it.”

— Chief Scott Galloway, Lafayette Indiana Police

“My experience using Draft One really blew me away. [...] A 25 to 30 minute long report...you hit the narrative button and it cranks something out in a few seconds.”

— Officer Nathan Stoneking, Lafayette Indiana Police

"With over 27 years of experience in law enforcement, I have seen technology come and go, but Draft One is one of the most exciting innovations for law enforcement I have ever seen."

— Sergeant Robert Younger, Fort Collins Colorado Police Services

Draft One is one of many examples of Axon’s commitment to innovating responsibly. Axon conducted a double-blind study to compare the quality between report narratives written with Draft One and those without. Results showed that Draft One performed equal to or better than officer-only report narratives across five dimensions, including completeness, neutrality, objectivity, terminology and coherence. In addition, we partnered with our Ethics & Equity Advisory Council (“EEAC”) to rigorously evaluate word choice selection, draft quality and potential racial bias. Input from Axon’s EEAC also included setting the default experience to limit report drafts to minor incident types and charge levels, and specifically excluding incidents where arrests took place and for felonies from the default settings. In practice, customers can still adjust from these default settings based on their specific preferences.

Axon VR Training

The Axon mobile app

Axon recognizes the versatile nature of law enforcement duties, which require presence both in the field and at the station. We also recognize the benefit of providing tools to increase officer efficiency, enabling our customers to get more done regardless of where they are. In fact, Axon’s 2024 Digital Evidence Trends Report found that 41% of officers return to the station multiple times per shift to review evidence or write reports. The same report also found that 55% of officers desire a mobile app that gives them the ability to review evidence in the field. In response, we have developed the Axon mobile app, which consolidates crucial features of the Axon ecosystem into one mobile platform.

The Axon mobile app is the first mobile app combining both digital evidence and records management into the same user interface. It enhances on-the-go accessibility and efficiency, and improves the experience for each user of our products, individually. Officers can handle evidence workflows and start and complete reports from the field, all without needing to return to the station. The app also includes a dynamic dashboard that provides a clear visual of action items


that require attention, and it allows officers to search for, review, request and maintain evidence including evidence categories, identification items, titles and other metadata. Over time, we plan to continue to build even more Axon experiences available in Axon’s desktop applications and into simplified mobile applications purpose-built inside this new unified, modern, mobile app.

“The main challenge is trying to keep up with all the digital evidence. You have to try to identify it, retain it and digest it all quickly.” — Commander Nicholas Sanders, Albuquerque Police Department

Axon believes better training will play a critical role in achieving our moonshot goal to cut gun-related deaths between police and the public in half by 2033. VR is a core technology powering our approach to help improve officer response and performance through more repetition, better practice in dynamic scenarios and more immersive experiences.

Over the last year, we introduced all-new ergonomically accurate TASER 10, TASER 7 and firearm VR controllers and expanded our training library to include more community engagement and de-escalation training modules. To take VR to the next level, we have now introduced Virtual Reality Based Training (“vRBT”) Live-Action, which incorporates 360 degree video immersions, featuring real human actors with realistic emotions and expressions, and vRBT Simulator CGI, which overlays VR training with interactive computer generated imagery (“CGI”) elements in 3D.

Now, Axon VR Training and TASER 10 are closely linked, and every TASER master instructor course includes VR training elements. Before these advances, TASER trainees would have limited experience with deploying a live TASER 10 due to budgetary limits on the number of cartridges that could be dedicated to training. VR democratizes TASER training across large and small agencies, enabling our customers to deploy hundreds of TASER 10 cartridges in VR at no incremental cost. In our newly introduced TASER 10 VR Validation Course, each trainee will deploy TASER 10 probes in VR on 40 different targets, which equates to a savings of more than $1,000 in real-world cartridges.

Strategic Ecosystem Expansion

Game-changing acquisition of Dedrone to accelerate next-generation drone solutions

Axon believes robotic security applications through drones and related technologies will play an enormous role in our mission to Protect Life. Today, Axon announced we have entered into a definitive agreement to acquire Dedrone, a global leader in airspace security. The acquisition of Dedrone is subject to customary closing conditions and is expected to close in the second half of 2024.

Dedrone is one of the most widely used and reliable counter-drone systems in the world, protecting the public by ensuring drone technology is used as a force for good. As unauthorized drone activity increases, enhanced airspace awareness and drone defense technology have become essential in ensuring public safety and national security. Dedrone can help rapidly detect, track, identify and, where permitted, mitigate drones and locate their pilots across multiple use cases both in civilian and professional security settings.

Dedrone’s technologies are also a key resource to expanding the authorized use of drones as first responders (“DFR”) in public safety. DFR programs are designed to deploy drones to a scene in advance of ground units, enhancing situational awareness to improve response strategies, optimizing the allocation of already limited resources and reducing the risk of harm to human officers.

Dedrone is another example of our execution on our investment strategy, which is geared to accelerate our product roadmap and enhance our ecosystem while building our talent base in product categories accretive to our long term growth. Dedrone follows our acquisitions of Sky-Hero and Fusus in the last 12 months and similarly complements our existing portfolio while expanding our product applications across our customer verticals. We estimate Dedrone will add approximately $14 billion to Axon’s total addressable market (“TAM”). In total, our acquisitions of Sky-Hero and Fusus and our planned acquisition of Dedrone would expand our TAM by more than 50% over the last year from $50 billion to $77 billion.

Q1 2024 Summary Results

Quarterly revenue of $461 million grew 34% year over year, exceeding our expectations driven by continued strength in Axon Cloud & Services, increasing adoption of TASER 10 driving growth in TASER devices and cartridges, and adoption of Axon Body 4.

Total company gross margin of 56.4% declined 310 basis points year over year driven by an increase in stock-based compensation expenses. Non-GAAP company gross margin of 63.2% increased 330 basis points year over year


driven by increased mix from high-margin Axon Cloud & Services revenue and the absence of one-time items related to inventory and other cost adjustments recognized in Q1 2023.

Increased stock-based compensation expense in our cost of goods sold (“COGS”) was related to enhanced equity compensation opportunities provided to employees with income below a certain threshold. This primarily impacted gross margin due to compensation rates for manufacturing and production employees relative to our broader employee base. We expect the total stock-based compensation expense from this program to be approximately $43 million for full year 2024. Axon is proud to set the bar for inclusive equity programs for all employees from the production line to the board room.

Operating profit of $16 million was approximately flat year over year, with higher revenue offset by increased stock-based compensation expenses in our COGS. Operating expenses as a percent of revenue improved to 52.9% as compared to 54.7% in Q1 2023 and included $45 million in stock-based compensation expenses.

COGS of $201 million, 43.6% of revenue, included $30 million in stock-based compensation expense.
SG&A expense of $153 million, 33.1% of revenue, included $23 million in stock-based compensation expense.
R&D expense of $91 million, 19.8% of revenue, included $22 million in stock-based compensation expense.

Net income of $133 million (28.9% net income margin, compared to 13.2% in Q1 2023), or $1.73 per diluted share, supported non-GAAP net income of $89 million (19.3% non-GAAP net income margin), or $1.15 per diluted share. The increase in net income year over year was primarily driven by unrealized gains related to our strategic investments, higher revenue and operating leverage.

Adjusted EBITDA of $109 million increased 67.3% year over year driven by higher revenue and operational leverage.

Both non-GAAP net income and Adjusted EBITDA exclude stock-based compensation expenses and net gains or losses related to our strategic investment portfolio.

Operating cash flow reflects a $16 million outflow in the quarter, an improvement of $40 million year over year and in-line with expected cash flow seasonality of prepaid expenses and other payments, such as company-wide bonus payouts and commission payments tied to strong 2023 performance.

As of March 31, 2024, Axon had $964 million in cash, cash equivalents and investments, and outstanding convertible notes in principal amount of $690 million, for a net cash position of $274 million, down $279 million sequentially, primarily driven by the closed acquisition of Fusus.

Financial commentary by segment

Software & Sensors

THREE MONTHS ENDED

CHANGE

 

    

31 MAR 2024

    

31 DEC 2023

    

31 MAR 2023

    

QoQ

    

YoY

(in thousands)

 

Axon Cloud & Services revenue(1)

$

176,467

$

163,632

$

116,453

 

7.8

%  

51.5

%

Axon Cloud & Services gross margin

 

72.8

%  

 

74.6

%  

 

73.2

%  

(180)

bp

(40)

bp

Axon Cloud & Services adjusted gross margin

74.5

%

75.2

%

73.8

%

(70)

bp

70

bp

Sensors & Other revenue

$

105,521

$

107,167

$

92,308

 

(1.5)

%  

14.3

%

Sensors & Other gross margin

 

38.7

%  

 

46.3

%  

 

38.2

%  

(760)

bp

50

bp

Sensors & Other adjusted gross margin

46.9

%

46.5

%

38.6

%

40

bp

830

bp


(1)The TASER segment includes Cloud and Services revenue, which is not included here.
Axon Cloud & Services revenue growth of 51.5% year over year was primarily driven by user growth and increasing adoption of premium add-on features related to Axon Evidence, real-time operations and productivity software.
Axon Cloud & Services gross margin of 72.8% decreased modestly from 73.2% year over year primarily due to increased stock-based compensation expense related to vesting events from a one-time enhanced equity compensation program and amortization expense of acquired intangible assets. Adjusted gross margin of 74.5% increased from 73.8% year over year due to increased mix to higher margin software revenues relative to low-margin professional services. Our software-only gross margin continues to exceed our target of 80%.

Sensors & Other revenue growth of 14.3% year over year was driven by growth in Axon Body cameras and accessories due to higher volumes, partially offset by lower Axon Fleet systems volumes on more normalized deployment timelines.
Sensors & Other gross margin of 38.7% increased modestly from 38.2% year over year as improvement from manufacturing overhead reallocations made in the second quarter of 2023 was offset by an increased stock-based compensation expense related to vesting events from a one-time enhanced equity compensation program. Sensors & Other adjusted gross margin of 46.9% increased from 38.6% year over year due to favorable product mix and manufacturing overhead reallocations made in the second quarter of 2023.

TASER

THREE MONTHS ENDED

CHANGE

 

    

31 MAR 2024

    

31 DEC 2023

    

31 MAR 2023

    

QoQ

    

YoY

(in thousands)

 

Revenue

$

178,748

$

161,343

$

134,282

 

10.8

%  

33.1

%

Gross margin

 

50.7

%  

 

57.1

%  

 

62.2

%  

(640)

bp

(1,150)

bp

Adjusted gross margin

61.8

%

57.6

%

62.4

%

420

bp

(60)

bp

TASER segment revenue growth of 33.1% year over year was driven by growth in professional devices and cartridges, associated with increased volumes of TASER 10, and Evidence & Cloud services, driven by increased connected devices in the field and growing adoption of VR products.
TASER segment gross margin of 50.7% decreased from 62.2% primarily due to increased stock-based compensation expense related to vesting events from a one-time equity compensation program. TASER segment adjusted gross margin of 61.8% was down modestly year over year from 62.4% due to higher product mix of TASER 10, which has not yet reached full scale production, partially offset by the absence of one-time items related to inventory and other cost adjustments recognized in Q1 2023.

Forward-looking performance indicators

    

31 MAR 2024

    

31 DEC 2023

    

30 SEP 2023

    

30 JUN 2023

    

31 MAR 2023

($ in millions)

 

Annual recurring revenue (1)

$

825

$

732

$

652

$

590

$

551

Net revenue retention (1)

 

122

%  

 

122

%  

 

122

%  

 

122

%  

 

121

%  

Total company future contracted revenue (1)

$

7,036

$

7,140

$

5,819

$

5,227

$

4,778


(1)Refer to “Statistical Definitions” below.
Annual recurring revenue grew 49.7% year over year to $825 million, driven by Axon Cloud & Services growth, which reflects growing demand for our high-value software subscription plans and a growing base of connected devices.
Net revenue retention was 122% in the quarter, reflecting our ability to deliver additional value to our customers over time and de minimis attrition. We drive adoption of our cloud software solutions through integrated subscription plans, which include a variety of premium software options. This Software-as-a-Service (“SaaS”) metric excludes the hardware portion of customer subscriptions and is normalized to account for phased customer deployments throughout the year.
Total company future contracted revenue of $7.0 billion decreased from $7.1 billion quarter over quarter due to normal first quarter bookings seasonality. We expect to recognize between 15% to 25% of this balance over the next 12 months, and generally expect the remainder to be recognized over the following ten years.

2024 Outlook


The following forward-looking statements reflect Axon’s expectations as of May 6, 2024, and are subject to risks and uncertainties. Please refer to “Forward-looking Statements” below for more information.

Axon expects full year 2024 revenue of $1.94 billion to $1.99 billion, representing approximately 26% annual growth at the midpoint. This is an increase from our prior revenue guidance range of $1.88 billion to $1.94 billion.

Axon expects full year 2024 Adjusted EBITDA dollars of $430 million to $445 million, implying Adjusted EBITDA margin of approximately 22%. This is an increase from our prior Adjusted EBITDA guidance range of $410 million to $430 million.
oWe provide Adjusted EBITDA guidance, rather than net income guidance, due to the inherent difficulty of forecasting certain types of expenses and gains such as stock-based compensation, income tax expenses and gains or losses on marketable securities and strategic investments, which affect net income but not Adjusted EBITDA. We are unable to reasonably estimate the impact of such expenses, which could be material, on net income. Accordingly, we do not provide a reconciliation of projected net income to projected Adjusted EBITDA.
We expect stock-based compensation expenses to be approximately $215 million to $230 million for the full year.
oFull year expected stock-based compensation expense includes approximately $43 million in expenses related to a one-time enhanced equity compensation program provided to employees whose compensation is under a specified threshold. We expect this expense to be primarily reflected within COGS. Approximately $30 million in stock-based expense related to this compensation opportunity was recognized in the first quarter, in-line with vesting schedules.
oBecause our stock-based compensation expenses may vary based on changes in our stock price or the actual timing of attainment of certain metrics, it is inherently difficult to forecast future stock-based compensation expense, which may also be materially affected by any future stock-based compensation plans, subject to shareholder approval.
We expect 2024 CapEx to be in the range of $80 million to $95 million, up from $60 million to $75 million previously. The increase in our CapEx expectations is primarily a result of accelerated capacity expansion investments to meet higher demand for TASER 10. Our 2024 CapEx plans include investments in TASER 10 automation and capacity expansion, including cartridge capacity and lab enhancements and global facility build-out and upgrades, such as warehousing support for global shipping facilities.


Quarterly conference call and webcast

We will host our Q1 2024 earnings conference call webinar on Monday, May 6th, 2 p.m. PT / 5 p.m. ET.

The webcast will be available via a link on Axon's investor relations website at https://investor.axon.com, or can be accessed directly via https://axon.zoom.us/j/91234146923.

Statistical Definitions

Annual recurring revenue: Annual recurring revenue is a performance indicator that management believes provides more visibility into the growth of our revenue generated by our highest margin, recurring services. Annual recurring revenue should be viewed independently of revenue and deferred revenue because it is an operating measure and is not intended to be combined with or to replace GAAP revenue or deferred revenue, as they can be impacted by contract start and end dates and renewal rates. Annual recurring revenue is not intended to be a replacement or forecast of revenue or deferred revenue. We calculate annual recurring revenue as monthly recurring license, integration, warranty, and storage revenue, annualized. As of the first quarter of 2024, in order to comprehensively cover recurring warranty revenue, we have recast our annual recurring revenue figures to include recurring TASER segment warranty revenue, in addition to the existing inclusion of recurring warranty revenue from our Software & Sensors segment.

Net revenue retention: Dollar-based net revenue retention is an important metric to measure our ability to retain and expand our relationships with existing customers. We calculate it as the software and camera warranty subscription and support revenue from a base set of agency customers from which we generated Axon Cloud subscription revenue in the last month of a quarter divided by the software and camera warranty subscription and support revenue from the year-ago month of that same customer base. This calculation includes high-margin warranty revenue but purposely excludes the lower-margin hardware subscription component of the customer contracts, as it is meant to be a SaaS metric that we use to monitor the health of the recurring revenue business we are building. This calculation also excludes the implied monthly revenue contribution of customers that were added since the year-ago quarter, and therefore excludes the benefit of new customer acquisition. The metric includes customers, if any, that terminated during the annual period, and therefore, this metric is inclusive of customer churn. This metric is downwardly adjusted to account for the effect of phased deployments—meaning that, for the year-ago period, we consider the total contractually obligated implied monthly revenue amount, rather than monthly revenue amounts that might have been in actuality smaller on a GAAP basis due to the customer not having yet fully deployed their Axon solution. For more information relative to our revenue recognition policies, please reference our filings with the Securities and Exchange Commission (“SEC”).

Total company future contracted revenue: Total company future contracted revenue represents remaining performance obligations and includes both recognized contract liabilities as well as amounts that will be invoiced and recognized in future periods. The remaining performance obligations are limited only to arrangements that meet the definition of a contract under Accounting Standards Codification Topic 606 as of March 31, 2024. We currently expect to recognize between 15% to 25% of this balance over the next 12 months, and generally expect the remainder to be recognized over the following ten years, subject to risks related to delayed deployments, budget appropriation or other contract cancellation clauses.

Non-GAAP Measures

To supplement the Company's financial results presented in accordance with GAAP, we present the non-GAAP financial measures of EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Margin, Non-GAAP Net Income, Non-GAAP Diluted Earnings Per Share, Free Cash Flow, and Adjusted Free Cash Flow. The Company's management uses these non-GAAP financial measures in evaluating the Company's performance in comparison to prior periods. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance, and when planning and forecasting our future periods. A reconciliation of GAAP to the non-GAAP financial measures is presented below.

EBITDA (Most comparable GAAP Measure: Net income) - Earnings before interest expense, investment interest income, income taxes, depreciation and amortization.
Adjusted EBITDA (Most comparable GAAP Measure: Net income) - Earnings before interest expense, investment interest income, income taxes, depreciation, amortization, non-cash stock-based compensation expense, fair value adjustments to strategic investments and marketable securities, transaction costs related to acquisitions and strategic investments, and other unusual, non-recurring pre-tax items that are not considered representative of our underlying operating performance (identified and listed below in the reconciliation).

Adjusted EBITDA Margin (Most comparable GAAP Measure: Net income margin) – Adjusted EBITDA as a percentage of net sales.
Adjusted Gross Margin (Most comparable GAAP Measure: Gross Margin) – Gross Margin before non-cash stock-based compensation expense and amortization of acquired intangible assets.
Non-GAAP Net Income (Most comparable GAAP Measure: Net income) - Net income excluding the costs of non-cash stock-based compensation, gain/loss/write-down/disposal/abandonment of property, equipment and intangible assets; fair value adjustments to strategic investments and marketable securities; transaction costs related to acquisitions and strategic investments; costs related to the Federal Trade Commission (“FTC”) litigation and antitrust litigation and other unusual, non-recurring pre-tax items that are not considered representative of our underlying operating performance (listed below). The Company tax-effects non-GAAP adjustments using the blended statutory federal and state tax rates for each period presented.
Non-GAAP Diluted Earnings Per Share (Most comparable GAAP Measure: Earnings Per share) - Measure of Company's Non-GAAP Net Income divided by the weighted average number of diluted common shares outstanding during the period presented.
Free Cash Flow (Most comparable GAAP Measure: Cash flow from operating activities) - Cash flows provided by operating activities minus purchases of property and equipment and intangible assets.
Adjusted Free Cash Flow (Most comparable GAAP Measure: Cash flow from operating activities) - Cash flows provided by operating activities minus purchases of property and equipment and intangible assets, excluding the net impact of investments in our new Scottsdale, Arizona campus and bond premium amortization.
oWe believe that free cash flow and adjusted free cash flow excluding the impact of bond premium amortization and net campus investment are non-GAAP measures that are useful to investors and management to evaluate the Company’s ability to generate cash. These non-GAAP measures can also be used to evaluate the Company’s ability to generate cash flow from operations and the impact that this cash flow has on the Company’s liquidity.

Caution on Use of Non-GAAP Measures

Although these non-GAAP financial measures are not consistent with GAAP, management believes investors will benefit by referring to these non-GAAP financial measures when assessing the Company's operating results, as well as when forecasting and analyzing future periods. However, management recognizes that:

these non-GAAP financial measures are limited in their usefulness and should be considered only as a supplement to the Company's GAAP financial measures;
these non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the Company's GAAP financial measures;
these non-GAAP financial measures should not be considered to be superior to the Company's GAAP financial measures; and
these non-GAAP financial measures were not prepared in accordance with GAAP or under a comprehensive set of rules or principles proposed by a third party.
Further, these non-GAAP financial measures may be unique to the Company, as they may be different from similarly titled non-GAAP financial measures used by other companies. As such, this presentation of non-GAAP financial measures may not enhance the comparability of the Company's results to the results of other companies.

About Axon

Axon is a technology leader in global public safety. Our moonshot goal is to cut gun-related deaths between police and the public by 50% before 2033. Axon is building the public safety operating system of the future by integrating a suite of hardware devices and cloud software solutions that lead modern policing. Axon’s suite includes TASER energy devices, body cameras, in-car cameras, cloud-hosted digital evidence management solutions, productivity software and


real-time operations capabilities. Axon’s growing global customer base includes first responders across international, federal, state and local law enforcement, fire, corrections and emergency medical services, as well as the justice sector, enterprises and consumers.

Non-Axon trademarks are property of their respective owners.

Axon, Axon Air, Axon Body, Axon Auto-Transcribe, Axon Evidence, Axon Fleet, Axon Records, Axon Respond, Axon Standards, Axon VR, Sky-Hero, TASER, TASER 7, TASER 10, Protect Life, the Filled Bolt within Circle Logo and the Delta Logo are trademarks of Axon Enterprise, Inc., some of which are registered in the United States and other countries. For more information, visit www.axon.com/legal. All rights reserved.

Forward-looking Statements

Forward-looking statements in this letter include, without limitation, statements regarding: proposed products and services and related development efforts and activities; expectations about the market for our current and future products and services, including statements related to our user base, customer profiles and TAM; the impact of pending litigation; strategies and trends relating to subscription plan programs and revenues; statements related to recently completed acquisitions; our anticipation that contracts with governmental customers will be fulfilled; the timing and realization of future contracted revenue; the fulfillment of bookings; strategies and trends, including the amounts and benefits of, R&D investments; the sufficiency of our liquidity and financial resources; expectations about customer behavior; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance, including our outlook for 2024 full year revenue, stock-based compensation expense, Adjusted EBITDA, Adjusted EBITDA margin, and capital expenditures; statements of management’s strategies, goals and objectives and other similar expressions; as well as the ultimate resolution of financial statement items requiring critical accounting estimates, including those set forth in our Annual Report on Form 10-K for the year ended December 31, 2023 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. Such statements give our current expectations or forecasts of future events; they do not relate strictly to historical or current facts. Words such as “may,” “will,” “should,” “could,” “would,” “predict,” “potential,” “continue,” “expect,” “anticipate,” “future,” “intend,” “plan,” “believe,” “estimate,” and similar expressions, as well as statements in future tense, identify forward-looking statements. However, not all forward-looking statements contain these identifying words.

We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans and assumptions. Achievement of future results is subject to risks, uncertainties and potentially inaccurate assumptions. The following important factors could cause actual results to differ materially from those in the forward-looking statements: our exposure to cancellations of government contracts due to appropriation clauses, exercise of a cancellation clause, or non-exercise of contractually optional periods; the ability of law enforcement agencies to obtain funding, including based on tax revenues; our ability to design, introduce and sell new products, services or features; our ability to defend against litigation and protect our intellectual property, and the resulting costs of this activity; our ability to win bids through the open bidding process for governmental agencies; our ability to manage our supply chain and avoid production delays, shortages and impacts to expected gross margins; the impacts of inflation, macroeconomic conditions and global events; the impact of catastrophic events or public health emergencies; the impact of stock-based compensation expense, impairment expense, and income tax expense on our financial results; customer purchase behavior, including adoption of our software as a service delivery model; negative media publicity or sentiment regarding our products; the impact of various factors on projected gross margins; defects in, or misuse of, our products; changes in the costs of product components and labor; loss of customer data, a breach of security, or an extended outage, including by our third party cloud-based storage providers; exposure to international operational risks; delayed cash collections and possible credit losses due to our subscription model; changes in government regulations in the United States and in foreign markets, especially related to the classification of our products by the United States Bureau of Alcohol, Tobacco, Firearms and Explosives; our ability to integrate acquired businesses; the impact of declines in the fair values or impairment of our investments, including our strategic investments; our ability to attract and retain key personnel; litigation or inquiries and related time and costs; and counter-party risks relating to cash balances held in excess of federally insured limits. Many events beyond our control may determine whether results we anticipate will be achieved. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected. You should bear this in mind as you consider forward-looking statements. Our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, which we expect to be available on May 7, 2024, lists various important factors that could cause actual results to differ materially from expected and historical results. These factors are intended as cautionary statements for investors within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Readers can find them in Part II, Item 1A under the heading “Risk Factors” in our Quarterly Reports on Form 10-Q, and investors should refer to them. You should understand that it is not possible to predict or identify all such factors. You should understand that it is not possible to predict or identify


all such factors. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.

Except as required by law, we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our Form 8-K, 10Q and 10K reports to the SEC. Our filings with the SEC may be accessed at the SEC’s web site at www.sec.gov.

Update on Legal Matters:

Antitrust Litigation/Inquiry Regarding 2018 Vievu Acquisition

Pending in the District of New Jersey (Case No. 3:23-cv-7182-RK-RLS) is a consolidated proposed class action lawsuit alleging Axon’s 2018 acquisition of Vievu LLC from Safariland LLC was anticompetitive, and that certain non-compete provisions in an ancillary holster supply agreement between Axon and Safariland unlawfully restrained trade. The complaint is based primarily on prior claims dismissed by the FTC without condition or consent decree. Axon denies the allegations and is vigorously defending the action.

Axon has served motions to dismiss all claims and to strike the class allegations on numerous grounds, including that Axon’s federal, state, and municipal customers with sovereign immunity cannot be absent class members. Motion practice is underway on Axon’s motion to dismiss and motion to strike class allegations, with rulings unlikely in 2024.  Discovery is stayed pending these rulings.

Axon has also received a recent request for information from the Pennsylvania Office of Attorney General regarding this same consummated Vievu transaction. Axon intends to cooperate with any such investigation and work to resolve any concerns of the Commonwealth of Pennsylvania.


AXON ENTERPRISE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

THREE MONTHS ENDED

    

31 MAR 2024

    

31 DEC 2023

    

31 MAR 2023

Net sales from products

$

272,048

$

258,405

$

219,389

Net sales from services

 

188,688

 

173,737

 

123,654

Net sales

 

460,736

 

432,142

 

343,043

Cost of product sales

 

151,698

 

125,664

 

107,584

Cost of service sales

 

48,992

 

42,591

 

31,357

Cost of sales

 

200,690

 

168,255

 

138,941

Gross margin

 

260,046

 

263,887

 

204,102

Operating expenses:

 

  

 

  

 

  

Sales, general and administrative

 

152,669

 

137,106

 

116,567

Research and development

 

91,097

 

83,972

 

70,927

Total operating expenses

 

243,766

 

221,078

 

187,494

Income from operations

 

16,280

 

42,809

 

16,608

Interest Income, net

10,374

12,325

9,666

Other income, net

 

139,066

 

668

 

15,610

Income before provision for income taxes

 

165,720

 

55,802

 

41,884

Provision for (benefit from) income taxes

 

32,502

 

(1,469)

 

(3,255)

Net income

$

133,218

$

57,271

$

45,139

Net income per common and common equivalent shares:

 

  

 

  

 

  

Basic

$

1.77

$

0.76

$

0.62

Diluted

$

1.73

$

0.75

$

0.61

Weighted average number of common and common equivalent shares outstanding:

 

  

 

  

 

  

Basic

 

75,355

 

75,060

 

72,638

Diluted

 

77,132

 

76,178

 

73,880


AXON ENTERPRISE, INC.

SEGMENT REPORTING

(in thousands)

THREE MONTHS ENDED

THREE MONTHS ENDED

THREE MONTHS ENDED

 

31 MAR 2024

31 DEC 2023

31 MAR 2023

 

  

  

Software

  

  

  

  

    

  

Software

    

  

  

  

  

  

Software

  

  

 

and

and

and

 

TASER

Sensors

Total

TASER

Sensors

Total

TASER

Sensors

Total

 

Net sales from products (1)

$

166,527

$

105,521

$

272,048

$

151,238

$

107,167

$

258,405

$

127,081

$

92,308

$

219,389

Net sales from services (2)

 

12,221

 

176,467

 

188,688

 

10,105

 

163,632

 

173,737

 

7,201

 

116,453

 

123,654

Net sales

 

178,748

 

281,988

 

460,736

 

161,343

 

270,799

 

432,142

 

134,282

 

208,761

 

343,043

Cost of product sales

 

86,984

 

64,714

 

151,698

 

68,067

 

57,597

 

125,664

 

50,583

 

57,001

 

107,584

Cost of service sales

 

1,074

 

47,918

 

48,992

 

1,096

 

41,495

 

42,591

 

180

 

31,177

 

31,357

Cost of sales

 

88,058

 

112,632

 

200,690

 

69,163

 

99,092

 

168,255

 

50,763

 

88,178

 

138,941

Gross margin

 

90,690

 

169,356

 

260,046

 

92,180

 

171,707

 

263,887

 

83,519

 

120,583

 

204,102

Gross margin %

  

 

50.7

%  

 

60.1

%  

 

56.4

%  

 

57.1

%  

 

63.4

%  

 

61.1

%  

 

62.2

%  

 

57.8

%  

 

59.5

%

Adjusted gross margin

61.8

%  

64.1

%  

63.2

%  

57.6

%

63.8

%

61.5

%

62.4

%

58.2

%

59.9

%


(1)Software and Sensors “products” revenue consists of sensors, including on-officer body cameras, Axon Fleet cameras, other hardware sensors, warranties on sensors, and other products, and is sometimes referred to as Sensors and Other revenue.
(2)Software and Sensors “services” revenue comprises sales related to the Axon Cloud and Services, which includes Axon Evidence, cloud-based evidence management software revenue, other recurring cloud-hosted software revenue and related professional services, and is sometimes referred to as Axon Cloud and Services revenue.


AXON ENTERPRISE, INC.

SALES BY PRODUCT AND SERVICE

(in thousands)

THREE MONTHS ENDED

31 MAR 2024

31 DEC 2023

    

31 MAR 2023

    

TASER segment:

TASER Devices (Professional)

$

98,676

 

21.4

%

$

94,758

21.9

%

$

67,472

 

19.7

%  

Cartridges

 

56,198

 

12.2

43,781

10.1

 

46,800

 

13.6

Axon Evidence and Cloud Services

 

12,221

 

2.7

10,105

2.4

 

7,201

 

2.1

Extended Warranties

 

8,526

 

1.8

8,226

1.9

 

7,670

 

2.2

Other (1)

 

3,127

 

0.7

4,473

1.0

 

5,139

 

1.5

Total TASER segment

 

178,748

 

38.8

161,343

37.3

 

134,282

 

39.1

Software and Sensors segment:

 

  

 

 

  

 

Axon Body Cameras and Accessories

 

51,205

 

11.1

58,957

13.7

 

38,797

 

11.3

Axon Fleet Systems

 

28,387

 

6.2

22,481

5.2

 

32,972

 

9.6

Axon Evidence and Cloud Services

 

175,458

 

38.1

165,204

38.2

 

118,314

 

34.5

Extended Warranties

 

18,474

 

4.0

17,272

4.0

 

14,085

 

4.1

Other (2)

 

8,464

 

1.8

6,885

1.6

 

4,593

 

1.4

Total Software and Sensors segment

 

281,988

 

61.2

270,799

62.7

 

208,761

 

60.9

Total net sales

$

460,736

 

100.0

%

$

432,142

100.0

%  

$

343,043

 

100.0

%  


(1)TASER segment “Other” includes smaller categories, such as VR hardware, weapons training revenue such as revenue associated with our Master Instructor School, and TASER consumer device sales.
(2)Software and Sensors segment “Other” includes revenue from items including Signal Sidearm, Interview Room, Axon Air and other sensors and equipment.


AXON ENTERPRISE, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(in thousands)

THREE MONTHS ENDED

    

31 MAR 2024

    

31 DEC 2023

    

31 MAR 2023

    

EBITDA and Adjusted EBITDA:

 

  

 

  

 

  

 

Net income

$

133,218

$

57,271

$

45,139

Depreciation and amortization

 

11,564

 

10,051

 

6,689

Interest expense

 

1,756

 

1,772

 

1,724

Investment interest income

 

(12,130)

 

(14,097)

 

(11,390)

Provision for (benefit from) income taxes

 

32,502

 

(1,469)

 

(3,255)

EBITDA

$

166,910

$

53,528

$

38,907

Adjustments:

 

  

 

  

 

  

Stock-based compensation expense

$

75,115

$

35,130

$

34,350

Unrealized gain on strategic investments and marketable securities, net

(97,419)

(521)

(15,570)

Gain on remeasurement of previously held minority interest, net

(42,292)

Transaction costs related to strategic investments and acquisitions

 

6,357

 

2,708

 

843

Loss on disposal, abandonment, and impairment of property, equipment and intangible assets, net

156

Costs related to antitrust and FTC litigations

 

224

 

169

 

Payroll taxes related to XSPP vesting and CEO Award option exercises

50

6,392

Adjusted EBITDA

$

108,895

$

91,064

$

65,078

Net income as a percentage of net sales

 

28.9

%  

 

13.3

%  

 

13.2

%  

Adjusted EBITDA as a percentage of net sales

 

23.6

%  

 

21.1

%  

 

19.0

%  

Stock-based compensation expense:

 

  

 

  

 

  

Cost of product and service sales

$

29,595

$

1,910

$

1,320

Sales, general and administrative

 

23,155

 

15,301

 

15,445

Research and development

 

22,365

 

17,919

 

17,585

Total

$

75,115

$

35,130

$

34,350


AXON ENTERPRISE, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - continued

(in thousands, except per share amounts)

THREE MONTHS ENDED

    

31 MAR 2024

    

31 DEC 2023

    

31 MAR 2023

    

Non-GAAP net income:

GAAP net income

$

133,218

$

57,271

$

45,139

Non-GAAP adjustments:

 

  

 

  

 

  

Stock-based compensation expense

 

75,115

 

35,130

 

34,350

Unrealized gain on strategic investments and marketable securities, net

 

(97,419)

 

(521)

 

(15,570)

Gain on remeasurement of previously held minority interest, net

(42,292)

Transaction costs related to strategic investments and acquisitions

 

6,357

 

2,708

 

843

Loss on disposal, abandonment, and impairment of property, equipment and intangible assets, net

 

 

 

156

Costs related to antitrust and FTC litigations

224

169

Payroll taxes related to XSPP vesting and CEO Award option exercises

50

6,392

Income tax effects

 

13,647

 

(9,391)

 

(6,660)

Non-GAAP net income

$

88,850

$

85,416

$

64,650

Diluted income per common share

GAAP

$

1.73

$

0.75

$

0.61

Non-GAAP

$

1.15

$

1.12

$

0.88

Weighted average number of diluted common and common equivalent shares outstanding (in thousands)

77,132

76,178

73,880


AXON ENTERPRISE, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - continued

(in thousands)

THREE MONTHS ENDED

    

31 MAR 2024

    

31 DEC 2023

    

31 MAR 2023

Net sales

$

460,736

$

432,142

$

343,043

 

Cost of sales

200,690

168,255

138,941

Gross margin

 

260,046

 

263,887

 

204,102

Stock-based compensation expense

29,595

1,910

1,320

Amortization of acquired intangible assets

1,686

Adjusted gross margin

$

291,327

$

265,797

$

205,422

Gross margin

56.4

%  

61.1

%  

59.5

%  

Adjusted gross margin

63.2

%  

61.5

%  

59.9

%  

Software and Sensors

THREE MONTHS ENDED

31 MAR 2024

31 DEC 2023

31 MAR 2023

Axon Cloud

Sensors

Axon Cloud

Sensors

Axon Cloud

Sensors

& Services

& Other

Total

& Services

& Other

Total

& Services

& Other

Total

New sales

$

176,467

$

105,521

$

281,988

$

163,632

$

107,167

$

270,799

$

116,453

$

92,308

$

208,761

Cost of sales

 

47,918

 

64,714

 

112,632

 

41,495

 

57,597

 

99,092

 

31,177

 

57,001

 

88,178

Gross margin

 

128,549

 

40,807

 

169,356

 

122,137

 

49,570

 

171,707

 

85,276

 

35,307

 

120,583

Stock-based compensation expense

 

1,502

 

8,312

 

9,814

 

964

 

233

 

1,197

 

697

 

313

 

1,010

Amortization of acquired intangible assets

 

1,348

 

338

 

1,686

 

 

 

 

 

 

Adjusted gross margin

$

131,399

$

49,457

$

180,856

$

123,101

$

49,803

$

172,904

$

85,973

$

35,620

$

121,593

Gross margin

 

72.8

%

 

38.7

%

 

60.1

%

 

74.6

%

 

46.3

%

 

63.4

%

 

73.2

%

 

38.2

%

 

57.8

%

Adjusted gross margin

  

 

74.5

%  

 

46.9

%  

 

64.1

%  

 

75.2

%  

 

46.5

%  

 

63.8

%  

73.8

%  

38.6

%  

58.2

%  

TASER

THREE MONTHS ENDED

    

31 MAR 2024

    

31 DEC 2023

    

31 MAR 2023

Net sales

$

178,748

$

161,343

$

134,282

 

Cost of sales

88,058

69,163

50,763

Gross margin

 

90,690

 

92,180

 

83,519

Stock-based compensation expense

19,781

713

310

Adjusted gross margin

$

110,471

$

92,893

$

83,829

Gross margin

50.7

%  

57.1

%  

62.2

%  

Adjusted gross margin

61.8

%  

57.6

%  

62.4

%  


AXON ENTERPRISE, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands)

    

31 MAR 2024

    

31 DEC 2023

(Unaudited)

ASSETS

 

  

 

  

Current Assets:

 

  

 

  

Cash and cash equivalents

$

403,870

$

598,545

Marketable securities

99,720

77,940

Short-term investments

 

560,186

 

644,054

Accounts and notes receivable, net

 

476,764

 

417,690

Contract assets, net

 

266,172

 

275,779

Inventory

 

271,318

 

269,855

Prepaid expenses and other current assets

 

123,677

 

112,786

Total current assets

 

2,201,707

 

2,396,649

Property and equipment, net

 

209,166

 

200,533

Deferred tax assets, net

 

208,861

 

229,513

Intangible assets, net

 

89,419

 

19,539

Goodwill

 

308,470

 

57,945

Long-term notes receivable, net

 

2,397

 

2,588

Long-term contract assets, net

88,209

 

77,710

Strategic investments

295,497

231,730

Other long-term assets

 

212,470

 

220,638

Total assets

$

3,616,196

$

3,436,845

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

  

 

  

Current Liabilities:

 

  

 

  

Accounts payable

$

82,075

$

88,326

Accrued liabilities

 

127,415

 

188,230

Current portion of deferred revenue

 

516,404

 

491,691

Customer deposits

 

21,979

 

21,935

Other current liabilities

 

9,601

 

9,787

Total current liabilities

 

757,474

 

799,969

Deferred revenue, net of current portion

 

293,878

 

281,852

Liability for unrecognized tax benefits

 

18,610

 

18,049

Long-term deferred compensation

 

14,700

 

11,342

Long-term lease liabilities

32,546

33,550

Convertible notes, net

 

677,895

 

677,113

Other long-term liabilities

3,078

2,936

Total liabilities

 

1,798,181

 

1,824,811

Stockholders’ Equity:

 

  

 

  

Preferred stock

 

 

Common stock

 

1

 

1

Additional paid-in capital

 

1,421,080

 

1,347,410

Treasury stock

 

(155,947)

 

(155,947)

Retained earnings

 

564,467

 

431,249

Accumulated other comprehensive loss

 

(11,586)

 

(10,679)

Total stockholders’ equity

 

1,818,015

 

1,612,034

Total liabilities and stockholders’ equity

$

3,616,196

$

3,436,845


AXON ENTERPRISE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

THREE MONTHS ENDED

    

31 MAR 2024

    

31 DEC 2023

    

31 MAR 2023

 

Cash flows from operating activities:

 

  

 

  

 

  

Net income

$

133,218

$

57,271

$

45,139

Adjustments to reconcile net income to net cash provided by (used in) operating activities:

 

 

  

 

Gain on strategic investments and marketable securities, net

 

(97,419)

 

(521)

 

(15,570)

Stock-based compensation

75,115

 

35,130

 

34,350

Gain on remeasurement of previously held minority interest, net

(42,292)

Deferred income taxes

 

20,670

 

(19,691)

 

(9,660)

Depreciation and amortization

 

11,564

 

10,051

 

6,689

Bond amortization

 

(4,990)

 

(4,378)

 

(3,890)

Noncash lease expense

1,795

1,956

1,395

Amortization of debt issuance cost

 

782

 

798

 

756

Unrecognized tax benefits

544

473

855

Other noncash items

461

2,389

1,047

Change in assets and liabilities:

 

 

 

Accounts and notes receivable and contract assets

 

(51,132)

 

9,944

 

(50,431)

Inventory

 

(710)

 

(12,332)

 

(15,811)

Prepaid expenses and other assets

 

2

 

(37,762)

 

(64,348)

Accounts payable, accrued and other liabilities

 

(84,289)

 

50,961

 

(37,043)

Deferred revenue

 

20,743

 

45,749

 

50,199

Net cash provided by (used in) operating activities

 

(15,938)

 

140,038

 

(56,323)

Cash flows from investing activities:

 

 

 

Purchases of investments

(241,457)

(118,995)

(145,124)

Proceeds from call / maturity of investments

330,472

196,204

81,088

Purchases of property and equipment

 

(16,194)

 

(24,011)

 

(8,513)

Purchases of intangible assets

(56)

(125)

Proceeds from disposal of property and equipment

34

31

Strategic investments

 

(9,128)

 

 

Business acquisition, net of cash acquired

 

(237,771)

 

 

Net cash provided by (used in) investing activities

 

(174,044)

 

53,173

 

(72,674)

Cash flows from financing activities:

 

 

 

Net proceeds from equity offering

 

 

 

33,650

Proceeds from options exercised

 

 

 

39,181

Income and payroll tax payments for net-settled stock awards

 

(2,710)

 

(3,818)

 

(34,841)

Net cash provided by (used in) financing activities

(2,710)

(3,818)

37,990

Effect of exchange rate changes on cash and cash equivalents

(1,978)

3,266

779

Net increase (decrease) in cash and cash equivalents and restricted cash

(194,670)

192,659

(90,228)

Cash and cash equivalents and restricted cash, beginning of period

600,670

408,011

355,552

Cash and cash equivalents and restricted cash, end of period

$

406,000

$

600,670

$

265,324


AXON ENTERPRISE, INC.

SELECTED CASH FLOW INFORMATION

(in thousands)

THREE MONTHS ENDED

    

31 MAR 2024

    

31 DEC 2023

    

31 MAR 2023

Net cash provided by operating activities

$

(15,938)

$

140,038

$

(56,323)

Purchases of property and equipment

 

(16,194)

 

(24,011)

 

(8,513)

Purchases of intangible assets

 

 

(56)

 

(125)

Free cash flow, a non-GAAP measure

$

(32,132)

$

115,971

$

(64,961)

Bond premium amortization

4,990

4,378

3,890

Net campus investment

1,033

606

1,012

Adjusted free cash flow, a non-GAAP measure

$

(26,109)

$

120,955

$

(60,059)

AXON ENTERPRISE, INC.

SUPPLEMENTAL TABLES

(in thousands)

    

31 MAR 2024

    

31 DEC 2023

(Unaudited)

Cash and cash equivalents

$

403,870

$

598,545

Short-term investments

 

560,186

 

644,054

Cash and cash equivalents and investments, net

964,056

1,242,599

Convertible notes, principal amount

(690,000)

(690,000)

Total cash and cash equivalents and investments, net of convertible notes

$

274,056

$

552,599


v3.24.1.u1
Document and Entity Information Document
May 06, 2024
Cover page.  
Document Type 8-K
Document Period End Date May 06, 2024
Entity Registrant Name Axon Enterprise, Inc.
Entity Central Index Key 0001069183
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 001-16391
Entity Tax Identification Number 86-0741227
Entity Address, Address Line One 17800 N. 85th St.
Entity Address, City or Town Scottsdale
Entity Address, State or Province AZ
Entity Address, Postal Zip Code 85255
City Area Code 480
Local Phone Number 991-0797
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.00001 Par Value
Trading Symbol AXON
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

Axon Enterprise (NASDAQ:AXON)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Axon Enterprise Charts.
Axon Enterprise (NASDAQ:AXON)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Axon Enterprise Charts.